Fenofibrate (also spelled Phenofibrate) is commonly prescribed for high cholesterol and high triglycerides. In 2017, it was the 70th most commonly prescribed medication in the United States with...
https://cureresearch4type1diabetes.blogspot.com/2024/05/fenofibrate-starts-phase-ii-trial.html
Siplizumab (MEDI-507, TCD601) is an monoclonal antibody which targets CD2 cells in the immune system. It is being developed by ITB-MED . It has an active research program for several diffe...
https://cureresearch4type1diabetes.blogspot.com/2024/04/siplizumab-starts-two-trials-in.html
This whole blog posting is very US (and US politics) focused, but the issues are similar in other countries. Also, this blog is trying to describe the existing situation, not argue that the cur...
https://cureresearch4type1diabetes.blogspot.com/2024/04/why-i-dont-blog-on-how-to-vote-for-t1d.html
My previous blog posting: https://cureresearch4type1diabetes.blogspot.com/2023/12/diamyd-update.html described the main line of DIAGNODE clinical trials designed to get Diamyd FDA approval for p...
https://cureresearch4type1diabetes.blogspot.com/2024/03/diamyd-update-part-2-jdrf-flexibilty-in.html
Levicure is a startup which is currently raising money to fund a phase-II trial for a combination therapy designed to prevent or delay T1D if given during the honeymoon period. This blog postin...
https://cureresearch4type1diabetes.blogspot.com/2024/03/levicures-combination-therapy.html
This clinical trial represents an attack on T1D slightly different than anything I've blogged on before. Pleconaril and Ribavirin are both antiviral drugs. The idea here is that viruses eithe...
https://cureresearch4type1diabetes.blogspot.com/2024/01/results-from-phase-ii-trial-of.html
Baricitinib (trade name Olumiant) is a drug which targets the immune system, and is already approved for Rheumatoid Arthritis (since 2018) and Alopecia Areata (since 2022). Since these two dise...
https://cureresearch4type1diabetes.blogspot.com/2024/01/results-from-phase-ii-baricitinib.html
At the start of a new year, some bloggers write a posting on the year that was, and a some write a posting on what they expect in the new year. This posting is a little of each. The Big News ...
https://cureresearch4type1diabetes.blogspot.com/2024/01/what-to-watch-in-2024.html
This is my first update on the Diamyd company in many, many years. It is focused on their DIAGNODE-3 clinical trial, but before I discuss that one study, I cover Diamyd's history, and after I d...
https://cureresearch4type1diabetes.blogspot.com/2023/12/diamyd-update.html
In this blog I'm going to report on three different clinical trials involving transplantation. The basic idea for all of these is to transplant beta cells into someone with T1D, and those new b...
https://cureresearch4type1diabetes.blogspot.com/2023/12/islet-cell-transplantation-clinical.html
Teplizumab (sold as Tzield) was recently approved for use in people at-risk of diagnosis for T1D. At risk meaning people who have two autoantibodies and abnormal blood glucose measurements, but...
https://cureresearch4type1diabetes.blogspot.com/2023/11/teplizumabtzield-reports-results-from.html
In the US, we are in the "Walking Season" when JDRF (Juvenile Diabetes Research Foundation) asks us to walk to raise money for a cure for type-1 diabetes. So I'd like to do my part, by reminding ...
https://cureresearch4type1diabetes.blogspot.com/2023/11/jdrf-funding-for-cure-2023.html
Difluoromethylornithine (DFMO), also known as Eflornithine, is FDA approved since 1990 as an injection to treat African Sleeping Sickness (trypanosomiasis) and since 2000 as a cream to prevent ex...
https://cureresearch4type1diabetes.blogspot.com/2023/10/dfmo-starts-phase-ii-clinical-trial.html
I've been blogging on research aimed at curing type-1 diabetes for over 15 years, and in that entire time, rarely have I rushed to blog on a new piece of research. That is because research prog...
https://cureresearch4type1diabetes.blogspot.com/2023/09/strong-results-from-pilot-study-of.html
This blog is a collection of smaller news items about T1D. COVID Not Likely to Increase T1D in Children From the beginning of COVID there has been an expectation that T1D rates would go up beca...
https://cureresearch4type1diabetes.blogspot.com/2023/07/t1d-research-news-quick-bits-for-july.html
CELZ-201 is a stem cell product, where the cells are isolated from the umbilical cord, Wharton’s jelly, placenta, amniotic membrane, and/or amniotic fluid and then treated in a proprietary way....
https://cureresearch4type1diabetes.blogspot.com/2023/06/celz-201-starts-phase-i-trial-create-1.html
Ladarixin is a drug being develop by Dompé (an Italian company). It inhibits activity on parts of the immune system called the IL-8 receptor (which has two subtypes: IL-8a and IL-8b). Dompé...
https://cureresearch4type1diabetes.blogspot.com/2023/05/dompe-starts-gladiator-phase-iii.html
This blog covers three pieces of news which do not apply directly to cure focused research, but which I found interesting anyway. Tight Honeymoon Control Does Not Improve Long Term Insulin Produc...
https://cureresearch4type1diabetes.blogspot.com/2023/04/t1d-research-news-quick-bits-from-april.html
Verapamil is a drug which has been used in the US since 1982 for high blood pressure, migraines, and heart problems. It also lowers levels of a protein called TXNIP. Some researchers believe ...
https://cureresearch4type1diabetes.blogspot.com/2023/03/results-from-phase-ii-verapamil-study.html
This is a straight forward clinical trial: people recently diagnosed with type 1 diabetes (in their honeymoon phase) will be given a standard flu vaccine to see if they will generate more of thei...
https://cureresearch4type1diabetes.blogspot.com/2023/03/influenza-vaccination-starts-phase-ii.html
Ixekizumab, sold under the trade name Taltz, blocks a specific part of the immune system called Interleukin 17 (IL-17). It has been approved since 2016 in the US and the EU as a treatment for P...
https://cureresearch4type1diabetes.blogspot.com/2023/02/ixekizumab-taltz-starts-phase-ii-trial.html
OPT101 is a peptide derived from mouse CD154. What does that mean? A peptide is a small part of a protein. CD154 is a protein found on some immune cells in both mice and people. CD154 is ...
https://cureresearch4type1diabetes.blogspot.com/2023/02/opt101-starts-phase-i-trial-in-adults.html
If you care about research aimed at curing type-1 diabetes, then you should care about JDRF's research funding. Year after year, they fund more than 2/3s of the research in clinical trials aime...
https://cureresearch4type1diabetes.blogspot.com/2022/12/youtube-video-describing-how-jdrf-makes.html
This is a phase-I, 10 person trial which started in September 2022, and is expected to finish in January 2024. This trial is for adults (18-50 years old, within 3 years of diagnosis). Half th...
https://cureresearch4type1diabetes.blogspot.com/2022/12/asdcc-starts-phase-i-clinical-trial-of.html
On 17-Nov-2022, The USA FDA approved Teplizumab. This is the first drug ever approved in the United States which changes the course of Type-1 Diabetes. This is a long blog which will discuss ...
https://cureresearch4type1diabetes.blogspot.com/2022/12/the-fda-approves-teplizumab-under-name.html